“Molnupiravir can be given to patients at home, unlike Gilead Sciences Inc.’s antiviral remdesivir and monoclonal antibody therapies, which are administered via an intravenous infusion usually in a hospital or a clinic.”
(Bloomberg) Merck & Co. and its partner Ridgeback Biotherapeutics LP sought emergency use authorization in the U.S. for molnupiravir, moving the pill closer to becoming the first oral antiviral treatment for Covid-19.
An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization, the companies said in a statement Monday. Submissions to regulatory authorities worldwide are expected in the coming months after interim analysis of clinical trial data found that it cut the risk of hospitalization for such patients by half.
The conservative voice and Christian content is being silenced more and more. CRN offers a lifeline to conservative people of faith who are disgusted with Facebook, Twitter and the MSM for failing to report, even blocking, important news stories that don’t comport with the far left’s narrative. We urge you to sign up to receive our FREE need to read articles. NO ADS! NO VIDEOS! NO POPUPS! JUST STRAIGHT NEWS.
Join Marsha West on MeWe